BioSpace News Archive

ZyVersa’s lead anti-inflammatory candidate, IC 100, is a novel monoclonal antibody that inhibits the ASC component of multiple types of inflammasomes, with potential to treat numerous inflammatory conditions

Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) (“Crescita” or the “Company”), today announced that it has entered into a distribution agreement (the “Agreement”) with Laboratoires FILLMED (formerly Laboratoires Filorga Medical, “FILLMED”) for the exclusive distribution of the ART-FILLER® injectables range and New Cellular Treatment Factor® (“NCTF®") in Canada

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid cannabinol (“CBN”) as the active pharmaceutical ingredient (“API”) in its two product candidates under development:

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a producer of high-grade cannabis extracted ingredients for the pharmaceutical, nutraceutical, therapeutical and cosmetic industries, is pleased to announce it has appointed Nick Davis as a new member on its Advisory Board.

TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today provided an update on its commercialization initiatives to bring its OTC Drug Identification Number (DIN) products and natural health products to market in 2020.

Crown Laboratories announced today that is has restructured its commercial operations business units as it continues to elevate its new “Skin Science for Life” commitment.

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced the establishment of Zhongjia Clean Technology (Wuhu) Co., Ltd (“Zhongjia”) a joint venture in Anhui Province, People’s Republic of China with Tus Qingyuan (Beijing) Si-Tech Co., Ltd (“Qingyuan”).

ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950).

Pharmatech Associates today announced the addition of Jahan Jowharchi as vice president, facilities and capital projects, to lead the expansion of the company’s service offering in all areas of pharmaceutical facility design and engineering.